[{"indications": "Indications\u00a0HIV infection in combination with other antiretroviral drugs", "name": "ABACAVIR", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test for HLA-B*5701 allele before treatment or if restarting treatment\r\nand HLA-B*5701 status not known\u2014increased risk of hypersensitivity\r\nreaction in presence of HLA-B*5701 allele; HIV load greater than 100\u00a0000 copies/mL; patients at high risk of cardiovascular disease (especially\r\nif 10-year cardiovascular risk greater than 20%); interactions: Appendix 1 (abacavir)Hypersensitivity reactions\u00a0Life-threatening hypersensitivity\r\nreactions reported\u2014characterised by fever or rash and possibly nausea,\r\nvomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise,\r\nheadache, and myalgia; less frequently mouth ulceration, oedema, hypotension,\r\nsore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia,\r\narthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal\r\nfailure; rarely myolysis; laboratory abnormalities may include raised\r\nliver function tests (\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nCautionsLactic acidosis\u00a0Life-threatening lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with nucleoside reverse transcriptase inhibitors. They should be used with caution in patients (particularly obese women) with hepatomegaly, hepatitis (especially hepatitis C treated with interferon alfa and ribavirin), liver-enzyme abnormalities and with other risk factors for liver disease and hepatic steatosis (including alcohol abuse). Treatment with the nucleoside reverse transcriptase inhibitor should be discontinued in case of symptomatic hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function. Stavudine, especially with didanosine, is associated with a higher risk of lactic acidosis and should be used only if alternative regimens are not suitable.) and creatine\r\nkinase; symptoms usually appear in the first 6 weeks, but may occur\r\nat any time; monitor for symptoms every 2 weeks for 2 months; discontinue immediately if any symptom of hypersensitivity develops\r\nand do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out,\r\neven when other diagnoses possible\u2014if rechallenge\r\nnecessary it must be carried out in hospital setting; if abacavir is stopped for any\r\nreason other than hypersensitivity, exclude hypersensitivity reaction\r\nas the cause and rechallenge only if medical assistance is readily\r\navailable; care needed with concomitant\r\nuse of drugs which cause skin toxicity Counselling\u00a0Patients should be told\r\nthe importance of regular dosing (intermittent therapy may increase\r\nthe risk of sensitisation), how to recognise signs of hypersensitivity,\r\nand advised to seek immediate medical attention if symptoms develop\r\nor before re-starting treatment; patients\r\nshould be advised to keep Alert Card with them at all times", "side-effects": "Side-effects\u00a0see notes above; also hypersensitivity reactions\r\n(see above); very rarely Stevens-Johnson syndrome\r\nand toxic epidermal necrolysis; rash and gastro-intestinal disturbances\r\nmore common in children", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/81977.htm", "doses": ["600\u00a0mg daily in 1\u20132 divided doses; child 3 months\u201318 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid (toxicity in animal studies); see also Pregnancy"}, {"indications": "Indications\u00a0HIV infection in combination with other antiretroviral drugs", "name": "ABACAVIR With lamivudine and zidovudine", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors", "ABACAVIR", "With lamivudine and zidovudine"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test for HLA-B*5701 allele before treatment or if restarting treatment\r\nand HLA-B*5701 status not known\u2014increased risk of hypersensitivity\r\nreaction in presence of HLA-B*5701 allele; HIV load greater than 100\u00a0000 copies/mL; patients at high risk of cardiovascular disease (especially\r\nif 10-year cardiovascular risk greater than 20%); interactions: Appendix 1 (abacavir)Hypersensitivity reactions\u00a0Life-threatening hypersensitivity\r\nreactions reported\u2014characterised by fever or rash and possibly nausea,\r\nvomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise,\r\nheadache, and myalgia; less frequently mouth ulceration, oedema, hypotension,\r\nsore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia,\r\narthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal\r\nfailure; rarely myolysis; laboratory abnormalities may include raised\r\nliver function tests (\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nCautionsLactic acidosis\u00a0Life-threatening lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with nucleoside reverse transcriptase inhibitors. They should be used with caution in patients (particularly obese women) with hepatomegaly, hepatitis (especially hepatitis C treated with interferon alfa and ribavirin), liver-enzyme abnormalities and with other risk factors for liver disease and hepatic steatosis (including alcohol abuse). Treatment with the nucleoside reverse transcriptase inhibitor should be discontinued in case of symptomatic hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function. Stavudine, especially with didanosine, is associated with a higher risk of lactic acidosis and should be used only if alternative regimens are not suitable.) and creatine\r\nkinase; symptoms usually appear in the first 6 weeks, but may occur\r\nat any time; monitor for symptoms every 2 weeks for 2 months; discontinue immediately if any symptom of hypersensitivity develops\r\nand do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out,\r\neven when other diagnoses possible\u2014if rechallenge\r\nnecessary it must be carried out in hospital setting; if abacavir is stopped for any\r\nreason other than hypersensitivity, exclude hypersensitivity reaction\r\nas the cause and rechallenge only if medical assistance is readily\r\navailable; care needed with concomitant\r\nuse of drugs which cause skin toxicity Counselling\u00a0Patients should be told\r\nthe importance of regular dosing (intermittent therapy may increase\r\nthe risk of sensitisation), how to recognise signs of hypersensitivity,\r\nand advised to seek immediate medical attention if symptoms develop\r\nor before re-starting treatment; patients\r\nshould be advised to keep Alert Card with them at all times", "side-effects": "Side-effects\u00a0see notes above; also hypersensitivity reactions\r\n(see above); very rarely Stevens-Johnson syndrome\r\nand toxic epidermal necrolysis; rash and gastro-intestinal disturbances\r\nmore common in children", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106113.htm", "doses": ["600\u00a0mg daily in 1\u20132 divided doses; child 3 months\u201318 years see BNF for Children", "Name[Trizivir\u00ae (ViiV) ] Tablets, blue-green, f/c, abacavir (as sulphate) 300\u00a0mg, lamivudine 150\u00a0mg, zidovudine\r\n300\u00a0mg, net price 60-tab pack = \u00a3509.06. \r\n    Label:\r\n    Counselling, hypersensitivity reactionsDose\u00a01 tablet twice daily; child under 18 years, body-weight over 30\u00a0kg see BNF for Children"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid (toxicity in animal studies); see also Pregnancy"}, {"indications": "Indications\u00a0HIV infection in combination with other antiretroviral drugs", "name": "ABACAVIR With lamivudine", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors", "ABACAVIR", "With lamivudine"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; also test for HLA-B*5701 allele before treatment or if restarting treatment\r\nand HLA-B*5701 status not known\u2014increased risk of hypersensitivity\r\nreaction in presence of HLA-B*5701 allele; HIV load greater than 100\u00a0000 copies/mL; patients at high risk of cardiovascular disease (especially\r\nif 10-year cardiovascular risk greater than 20%); interactions: Appendix 1 (abacavir)Hypersensitivity reactions\u00a0Life-threatening hypersensitivity\r\nreactions reported\u2014characterised by fever or rash and possibly nausea,\r\nvomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise,\r\nheadache, and myalgia; less frequently mouth ulceration, oedema, hypotension,\r\nsore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia,\r\narthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal\r\nfailure; rarely myolysis; laboratory abnormalities may include raised\r\nliver function tests (\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nCautionsLactic acidosis\u00a0Life-threatening lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with nucleoside reverse transcriptase inhibitors. They should be used with caution in patients (particularly obese women) with hepatomegaly, hepatitis (especially hepatitis C treated with interferon alfa and ribavirin), liver-enzyme abnormalities and with other risk factors for liver disease and hepatic steatosis (including alcohol abuse). Treatment with the nucleoside reverse transcriptase inhibitor should be discontinued in case of symptomatic hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function. Stavudine, especially with didanosine, is associated with a higher risk of lactic acidosis and should be used only if alternative regimens are not suitable.) and creatine\r\nkinase; symptoms usually appear in the first 6 weeks, but may occur\r\nat any time; monitor for symptoms every 2 weeks for 2 months; discontinue immediately if any symptom of hypersensitivity develops\r\nand do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out,\r\neven when other diagnoses possible\u2014if rechallenge\r\nnecessary it must be carried out in hospital setting; if abacavir is stopped for any\r\nreason other than hypersensitivity, exclude hypersensitivity reaction\r\nas the cause and rechallenge only if medical assistance is readily\r\navailable; care needed with concomitant\r\nuse of drugs which cause skin toxicity Counselling\u00a0Patients should be told\r\nthe importance of regular dosing (intermittent therapy may increase\r\nthe risk of sensitisation), how to recognise signs of hypersensitivity,\r\nand advised to seek immediate medical attention if symptoms develop\r\nor before re-starting treatment; patients\r\nshould be advised to keep Alert Card with them at all times", "side-effects": "Side-effects\u00a0see notes above; also hypersensitivity reactions\r\n(see above); very rarely Stevens-Johnson syndrome\r\nand toxic epidermal necrolysis; rash and gastro-intestinal disturbances\r\nmore common in children", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129292.htm", "doses": ["600\u00a0mg daily in 1\u20132 divided doses; child 3 months\u201318 years see BNF for Children", "Name[Kivexa\u00ae (ViiV) ] Tablets, orange, f/c, abacavir (as sulphate) 600\u00a0mg, lamivudine 300\u00a0mg, net\r\nprice 30-tab pack = \u00a3352.25. \r\n    Label:\r\n    Counselling, hypersensitivity reactionsDose\u00a0adult body-weight\r\nover 40\u00a0kg, 1 tablet once daily; child 12\u201318 years see BNF for Children "], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid (toxicity in animal studies); see also Pregnancy"}]